Tuesday, December 06, 2016 2:17:21 PM
*********************
Conclusions and Future Directions
Presentation Number: 4650, Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary
Data From The DURGA Trial – Daniel Morgensztern, MD
• There have been no additional toxicities for combination of Viagenpumatucel-L plus nivolumab compared to
existing data on single agent immune checkpoint inhibitors alone.
• Immune responses may correlate with clinical efficacy
• The phase 1b part of the study is still ongoing and the expansion phase will be determined based on the
preliminary ORR
• Additional combinations with chemotherapy, anti-CTLA-4 and other T-cell co-stimulators being considered
• Manufacturing started for the second generation vaccine ComPACT, which incorporates OX40-L costimulatory molecule
********************
It is the "additional combinations" which most interests me. It could mean many new arms to the DURGA trial. I would expect a Opdivo/Yervoy + HS-110 and/or HS-120 arm. As for chemotherapy combinations....might they add low-dose cyclophosphamide to some of these combinations? They have some experience with it!
"The refusal of the real is the number one dogma of our time" Rene Girard
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM